160 related articles for article (PubMed ID: 22215850)
1. Drug approvals 2011: focus on companion diagnostics.
Goozner M
J Natl Cancer Inst; 2012 Jan; 104(2):84-6. PubMed ID: 22215850
[No Abstract] [Full Text] [Related]
2. Larger companies dominate cancer companion diagnostic approvals.
Schmidt C
Nat Biotechnol; 2011 Nov; 29(11):955-7. PubMed ID: 22068512
[No Abstract] [Full Text] [Related]
3. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Döme B; Magyar M
Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
[TBL] [Abstract][Full Text] [Related]
4. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Török S; Cserepes T M; Rényi-Vámos F; Döme B
Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
[TBL] [Abstract][Full Text] [Related]
5. Challenges ahead for companion diagnostics.
Schmidt C
J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
[No Abstract] [Full Text] [Related]
6. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
7. NSCLC drug targets acquire new visibility.
Friedrich MJ
J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
[No Abstract] [Full Text] [Related]
8. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
9. Seattle Genetics rare cancer drug sails through accelerated approval.
DeFrancesco L
Nat Biotechnol; 2011 Oct; 29(10):851-2. PubMed ID: 21997610
[No Abstract] [Full Text] [Related]
10. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
11. New targeted therapies in melanoma.
Kudchadkar RR; Gonzalez R; Lewis K
Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
13. Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?
Retsas S
J R Soc Med; 2011 Jun; 104(6):269-72. PubMed ID: 21659402
[No Abstract] [Full Text] [Related]
14. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.
Atherly AJ; Camidge DR
Br J Cancer; 2012 Mar; 106(6):1100-6. PubMed ID: 22374459
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.
Qian H; Gao F; Wang H; Ma F
BMC Cancer; 2014 Sep; 14():683. PubMed ID: 25239305
[TBL] [Abstract][Full Text] [Related]
16. [Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].
Monneret C
Ann Pharm Fr; 2013 Mar; 71(2):95-103. PubMed ID: 23537410
[TBL] [Abstract][Full Text] [Related]
17. Current Molecularly Targeting Therapies in NSCLC and Melanoma.
Rajanna S; Rastogi I; Wojdyla L; Furo H; Kulesza A; Lin L; Sheu B; Frakes M; Ivanovich M; Puri N
Anticancer Agents Med Chem; 2015; 15(7):856-68. PubMed ID: 25642982
[TBL] [Abstract][Full Text] [Related]
18. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
19. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Twombly R
J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
[No Abstract] [Full Text] [Related]
20. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
